Bayer Ag · XETR:BAYN
Bayer — Investor Presentation (April 2022)
77 slides from Bayer's investor presentation, April 2022
Slide 1: A Global Leader in Health & Nutrition
Science for a Better Life A Global Leader in Health & Nutrition /////////// Investment Case April 2022 / Bayer AG 1 /// Bayer AG /// Investment Case /// April 2022
Slide 2: Cautionary Statements Regarding Forward-Looking Information
Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the ac
Slide 3: Bayer: A Global Leader in Health and Nutrition
Group Overview Winning Portfolio Bayer: A Global Leader in Health and Nutrition Well Positioned to Create Value in Growing Markets using Science to Address Societal Megatrends Market Size Crop Science Bayer Group Sales ~€100bn1 #3 OTC Player Consumer #1 in Sales and Health Profitability & R&D Crop S
Slide 4: Global Megatrends in Health & Nutrition
Group Overview Global Megatrends in Health & Nutrition Attractive Macro Drivers of Our Strategy and Underpin the Need for Innovation Pharmaceuticals Consumer Health Crop Science Aging Population Growing Population Pressure on Ecosystems Megatrends People 60+ +2.2bn +50% -20% more than people1 throug
Slide 5: Leadership and Innovation Set the Course for Our Future Growth
Group Overview Leadership and Innovation Set the Course for Our Future Growth Key Growth Drivers Long-term megatrend tailwinds are propelling growing demand in the Life Sciences Number one position in Ag inputs and leading positions in key Pharma and Consumer categories World-class innovation: techn
Slide 6: New Transformation Program with Gross Contributions of >€1.5bn
Group Overview New Transformation Program with Gross Contributions of >€1.5bn Expect Partial Reinvestment to Drive New Opportunities; Remainder to Drive Margin Expansion Transformation Programs Delivery €2.6bn • Bayer 2022 program successfully concluded > €1.5bn • We accelerate our transformation to
Slide 7: Focus on Cash Generation Now Embedded in Incentive Plans
Group Overview Focus on Cash Generation Now Embedded in Incentive Plans Improvements Expected from Sales Growth, Working Capital & Divestments; Litigation Pay-outs and One- Time Costs for Transformation Mitigating Factors Improve Free Cash Flow Adapt incentive scheme Free Cash Flow integrated as a k
Slide 8: Disciplined Capital Allocation to Delever, Pay Dividends and Invest
Group Overview Disciplined Capital Allocation to Delever, Pay Dividends and Invest Expect Net Debt to Return to €28-30bn by 2024 Capital allocation priorities Net financial debt development In €bn 33 33-34 Rating target: 28-30 Deleveraging A category 3.4 Free Cash Flow 2.8- Pay-out range: 3.0 Divide
Slide 9: Sustainability is Integral to Our Values, Strategy and Operations
Group Overview Sustainability is Integral to Our Values, Strategy and Operations We intend to create bold impact and generate sustainable business opportunities Pharmaceuticals Consumer Health Crop Science Megatrends Aging Population Growing Population Pressure on Ecosystems Preserve and Secure suff
Slide 10: Investment Thesis: Key Takeaways
Key Takeaways Group Overview Investment Thesis Key Takeaways 1 We are a global leader in Health & Nutrition that addresses societal megatrends 2 We are well-positioned to shape disruption in the bio-revolution 3 We expect to translate innovation into profitable mid-term growth 4 We expect to improve
Slide 11: Shaping the Future of Agriculture
Science for a Better Life Shaping the Future of Agriculture /////////// Investment Case April 2022 / Bayer AG 11 /// Bayer AG /// Investment Case /// April 2022
Slide 12: Shaping the Future of Agriculture
Shaping the Future of Agriculture 1 Market & Position 4 World-Class Innovation 2 Strategy 5 Digital Transformation 3 Operational Performance 6 New Standards in Sustainability 12 /// Bayer AG /// Investment Case /// April 2022
Slide 13: The Established Leader in Crop Science
1 Market & Position The Established Leader in Crop Science Industry Leading Sales, Profitability and Unmatched Investment in R&D to Fund Future Growth Largest in Sales Highest Profitability Total Sales1 (€bn) EBITDA1 (€bn) / EBITDA1 Margin (%) 11.2 9.0 20,2 4,7 23.2% Syngenta 16,2 Syngenta 3,2 19.6%
Slide 14: Global #1 in Seed & Traits with Leading Crop Protection Portfolio
1 Market & Position Global #1 in Seed & Traits with Leading Crop Protection Portfolio Sales by Region – Bayer Crop Science Market Positions1 Product areas – Bayer Crop Science In %, based on sales 2021 €20.2bn In %, in 2021 €20.2bn Corn S&T #1 Other Soybean S&T #1 Vegetable Seeds Corn Seed & North 2
Slide 15: Megatrends Drive Market Growth and Need for Innovation
1 Market & Position Megatrends Drive Market Growth and Need for Innovation Ag Market Remains Attractive with Expected ~3% CAGR1 to 2030 Expected 10 Yr. Global Ag Input Market Growth Rate Demand Supply 50% 17% Harvest losses 3% More food, feed from climate CAGR & biofuel2 needed change2 2020E Global
Slide 16: Win by being more grower centric
2 Strategy Purpose Shaping agriculture for the benefit of farmers, consumers and the planet Strategic Perform Transform Ambition Grow above market and deliver Achieve 100% digitally enabled strong returns sales by 2030 PillarsOperational Performance World Class Innovation Digital Transformation New
Slide 17: A Clear Plan to Accelerate Growth and Outperform the Market
3 Operational Performance A Clear Plan to Accelerate Growth and Outperform the Market 1 Deliver growth in crop protection sales through new products, integrated offerings 2 Grow corn seed & traits with annual portfolio refresh and new insect traits 3 Upgrade the Americas to next-gen soybean trait te
Slide 18: Progressing from Volume to Value with Our Crop Protection Vision
3 Operational Performance Progressing from Volume to Value with Our Crop Protection Vision Today Future Enhanced by Digital Farming Leading Portfolio Solutions Convergence of Advances in Small Molecules, Biology and Biotechnology Innovation with Digital Technology to Create New Value and Sustainable
Slide 19: Herbicides: Focused on Unlocking Greater Flexibility
3 Operational Performance Herbicides: Focused on Unlocking Greater Flexibility Herbicide sales in 2021: €5.3bn, Pipeline Peak Sales Potential of ~€3bn • Pyroxasulfone 3 New Herbicide • First new mode of action in post MoA • Diflufenican emergence weed control in 30 Molecule years • Aclonifen NEW • M
Slide 20: Fungicides: New Innovations Drive our Growth Potential
3 Operational Performance Fungicides: New Innovations Drive our Growth Potential Fungicide sales in 2021: €2.9bn, Pipeline Peak Sales Potential of ~€4bn 3 • Includes next-gen • Prothioconazole • Powered by technology Indiflin®1, • Trifloxystrobin Fluoxapiprolin with Prothioconazole MoA • Fluopyram •
Slide 21: Insecticides: New Launches Drive our Global Expansion
3 Operational Performance Insecticides: New Launches Drive our Global Expansion Insecticide sales in 2021: €1.4bn, Pipeline Peak Sales Potential of ~€2bn • Fast-acting and long-lasting • First ketoenol insecticide control of all important expected to offer both foliar and caterpillars and selected P
Slide 22: Biologicals Create New Value; Enable Crop Management Benefits
3 Operational Performance Biologicals Create New Value; Enable Crop Management Benefits Leveraging the Power and Sustainability Derived from Microbes Bayer is the #1 Trusted Brand in Biologicals by Growers4 SeedGrowth Foliar & Soil applied Crop Soilborn Performance Corn Yield Soy Yield Nematicide Fu
Slide 23: Deploying >250 Corn Hybrids in 2021 to Expand Leading Position
3 4 Operational Performance Deploying >250 Corn Hybrids in 2021 to Expand Leading Position Foundational to Expected Growth in Our > €5bn Global Annual Corn Seed & Trait Sales Mid-Term Key Growth Drivers in Corn NEW Superior-performing Bayer branded hybrids capture #1 Launching CRW3 as a part of VTPr
Slide 24: Upgrading the Americas to Next-Gen Soybean Trait Technology
3 New Standards Operational Performance in Sustainability Upgrading the Americas to Next-Gen Soybean Trait Technology United States and Canada Bayer Soybean Trait Offerings: # 1 Market Pos. LAUNCHED 2020 2021 2027 F HT4 1 South America Industry’s First # Five-Tolerance Market Pos. Bayer Soybean Trai
Slide 25: Multiple Traits in Late-Stage Development for Cotton Farmers
3 Operational biotech Performance Fourth-Gen Phase 3 Multiple Traits in Late-Stage Development for Cotton Farmers Leading Innovation for Cotton Growers Driving Growth in >€500m1 Cotton S&T Business 1st generation 5 herbicide tolerances 4th generation • Glyphosate • HPPD • Season-long protection with
Slide 26: Unmatched R&D Investment Powers Industry-Leading Portfolio
5 4 World-Class Leadership Innovation Unmatched R&D Investment Powers Industry-Leading Portfolio Ag R&D Investment (€bn) 2,0 #1 R&D Platform in Crop Science 1,2 1,0 0,9 >7,100 R&D employees3 Bayer Crop Science 1 Syngenta + Adama 2 Corteva BASF Ag >100 key Ag Chem Seed & Traits collaborations; partne
Slide 27: Pipeline with Up to €30bn Peak Sales Potential Delivering for Farmers
4 World-Class Innovation Pipeline with Up to €30bn Peak Sales Potential Delivering for Farmers Eight Projects Advance, Eight New Formulations Launch and Hundreds of Seed Deployments in 2021 Value of Up to €30bn >300 New crop in Cumulative Peak Sales Potential1 >500 protection ~50% Incremental regist
Slide 28: Short-Stature Corn Offers Transformational Shift in Production
4 World-Class Innovation Short-Stature Corn Offers Transformational Shift in Production Anticipated Fit on >220m Acres and Estimated Incremental Peak Sales Potential of ~€1bn for NA Field Plots Around the Globe Demonstrate Key Features and Benefits of Short-Stature Corn Game-Changing Innovation Digi
Slide 29: Three Generations of Soybean Herbicide Tolerance Traits
4 World-Class Innovation Three Generations of Soybean Herbicide Tolerance Traits Technologies Provide Solutions to Address Farmer’s Needs, Herbicide Resistance Challenges 3 herbicide tolerances 5 herbicide tolerances 6 herbicide tolerances • Glyphosate • Glyphosate • Glyphosate HT4 HT5 • Dicamba • D
Slide 30: Digital Farming Solutions Underpin and Enhance Our Ability to Bring Transformational Solutions
5 Digital data science Transformation Digital Farming Solutions Underpin and Enhance Our Ability to Bring Transformational Solutions to Agriculture Our Positive Impact on Agriculture Three Core Value Drivers • Increase yield and improve profitability Franchise Value • Leverage information to manage
Slide 31: Climate FieldView Provides Unmatched Visualization, Analysis and Insights
5 Digital data science Transformation Climate FieldView Provides Unmatched Visualization, Analysis and Insights to Enable Growers to Enhance Productivity Climate FieldView • >180m subscribed acres • Largest database of grower and field trial seed • #1 brand in digital ag1 performance data in industr
Slide 32: Digital Unlocks Scalable Climate-Smart Business Models
5 Digital data science Transformation Digital Unlocks Scalable Climate-Smart Business Models Carbon Markets Valued at >$200bn/year1 and Growing with Consumers' Demand for Sustainability has the potential to Carbon Initiative streamline the way carbon is measured, verified and reported, to enable sca
Slide 33: Enabling New Digital Platforms in Ag
5 Digital data science Transformation Enabling New Digital Platforms in Ag Opens Access to Participate in Broader B2B AgTech Value Pools; Expanding into Digital Marketplaces Orbia: First Digital Ag-Marketplace Collaboration • JV between Bayer and Bravium1 • Connects growers, input providers and grai
Slide 34: Setting the Standard for Sustainability and Biodiversity in Agriculture
6 New Standards in Sustainability Setting the Standard for Sustainability and Biodiversity in Agriculture Bayer’s 2030 Sustainability Commitments Advancing a carbon-zero future for agriculture 30 Reduction of field • Climate-smart practices: • No-tillage Highly Productive Crops • Cover Crops Precisi
Slide 35: Pharmaceuticals: Driving Continued Long-term Growth
Science for a Better Life Pharmaceuticals: Driving Continued Long-term Growth /////////// Investment Case April 2022 / Bayer AG 35 /// Bayer AG /// Investment Case /// April 2022
Slide 36: Pharmaceuticals: Driving Continued Long-Term Growth
Pharmaceuticals: Driving Continued Long-Term Growth 1 Market & Position 2 Strategy 3 Growth Drivers 4 Innovation 36 /// Bayer AG /// Investment Case /// April 2022
Slide 37: Operating in a Rapidly Changing but Attractive Market Environment
1 Market & Position We are Operating in a Rapidly Changing but Attractive Market Environment Driven by Megatrends and the Bio Revolution Pharma Market Market Dynamics Market Size 2021e1 Opportunities Japan • Aging and growing population megatrends China 7% • Rising life expectancy and increased acce
Slide 38: Bayer Pharmaceuticals Holds Strong Positions in Areas of High Unmet Medical Needs
1 Market & Position Bayer Pharmaceuticals Holds Strong Positions in Areas of High Unmet Medical Needs, Generating Growth and Attractive Returns Bayer Pharmaceuticals – Sales and EBITDA margin before special items 2011-20211) Sales by therapeutic area In % for 2021 Other EBITDA Sales margin before He
Slide 39: Strong Volume Expansion in FY 2021
1 Market & Position Strong Volume Expansion in FY 2021 Sales Sales EBITDA Key Messages InIn million €,€, million ∆% yoy, ∆% yoycpa. In million €, before special items • Solid topline growth after COVID-19 related restrictions in prior year Volume +6% • Flagship products performed particularly +9% (+
Slide 40: Our Strategy is Geared Towards Continued and Sustainable Long-term Growth
2 Strategy Our Strategy is Geared Towards Continued and Sustainable Long- term Growth, also Addressing Loss of Exclusivity of Major Products Capture the value of the current portfolio and manage LoE for Xarelto & Eylea Grow new potential blockbusters Build digital health solutions Capitalize on Cell
Slide 41: Successfully Launched Four New Drugs and Strengthened Pipeline
2 Strategy Over the Last Three Years we Successfully Launched Four New Drugs and Strengthened Pipeline and Technologies Main Building Blocks of Post LoE Growth 1 Late-stage Pipeline Elinzanetant (KaNDy NT-814) in CV & WH PSP ~ €0.5bn PSP ≥ €1.0bn PSP ≥ €1.0bn launched in 2021 launched in 2021 potent
Slide 42: Capturing the Full Commercial Potential of Market Leading Therapies
3 Growth Drivers Capturing the Full Commercial Potential of Market Leading Therapies Guidance FY2022 Guidance FY2022 Higher volumes to largely offset Mid-single digit growth 12 months impact of VBP2 in China New indications & label updates in 2021 2 Phase III studies with high-dose formulation (init
Slide 43: Kerendia is a Game Changer for CKD and Type 2 Diabetes Patients
3 Growth Drivers Kerendia is a Game Changer for CKD and Type 2 Diabetes Patients Next milestone in renal disease treatment, continuing our RAAS-centric treatment history Largest clinical program Successful launch trajectory Entresto with unparalleled data1 2020 Weekly TRx (US) Novel MOA intensifies
Slide 44: Kerendia sets the stage for a long-term cardio-renal vision
Kerendia sets the stage for a long-term cardio-renal vision and targets to deliver blockbuster potential Unmet Needs Kidney Dedicated CardioRenal Disease Modifier Need for RAASi intensification Need for earlier use in disease progression Need for disease Establish Kerendia as the Heart failure Non-d
Slide 45: Significantly Expand our Presence in Selected Areas of Oncology
3 Growth Drivers We are Targeting to Significantly Expand our Presence in Selected Areas of Oncology where One Blockbuster can Build a Franchise Key elements to achieve our growth aspiration • Continue to build strong prostate cancer franchise with NUBEQA and Xofigo • Realize >€3bn peak sales potent
Slide 46: Prostate Cancer is #2 of the Most Common Cancer Types in Men
3 Growth Drivers Prostate Cancer is at #2 of the Most Common Cancer Types in Men Worldwide with Significant Unmet Medical Need Estimated number of new cases in 2020, worldwide, males, all ages Characteristics of Prostate Cancer • Usual onset: age >50 years Lung 1,435,943 (14.3%) Other cancers • Diag
Slide 47: Two Highly Consistent Phase 3 Studies Confirm Nubeqa's Strong Clinical Profile
3 Growth Drivers Two Highly Consistent Phase 3 Studies Confirm Nubeqa’s Strong Clinical Profile in Prostate Cancer Treatment Efficacy Study Primary endpoint Selected secondary endpoints Tolerability ARAMIS Metastasis free survival Overall survival nmCRPC prolongation by 22.0 months, 31% risk reducti
Slide 48: Committed to Make Nubeqa Available to a Broad Spectrum of Prostate Cancer Patients
3 Growth Drivers We Are Committed to Make Nubeqa Available to a Broad Spectrum of Prostate Cancer Patients Patient progression in prostate cancer ~10-15 years (Neo-)Adjuvant Nonmetastatic Metastatic early-stage mid-stage late-stage BCR4 nmCRPC3 mHSPC2 mCRPC1 G7 Drug treated epidemiology ~145k ~85k ~
Slide 49: Nubeqa With the Chance to Become a Foundational Drug
3 Growth Drivers Nubeqa With the Chance to Become a Foundational Drug to Treat Prostate Cancer – Peak Sales Potential of >€3bn • Highly efficacious ARi1 Strong launch performance in nmCRPC • Very consistent set of data from two Weekly TRx (US) Efficacy Phase 3 studies 400 • First to show more than 3
Slide 50: Our Innovation Engine is Delivering
4 Innovation Our Innovation Engine is Delivering 2 Committed and experienced External new leadership team Innovation 1 3 Advancing leading cell and Internal Platform gene therapy business Innovation Companies World leading science added 1 2 3 through new platforms Global R&D Collaborations, CGT SMOL
Slide 51: External Innovation to Accelerate Replenishment of Pipeline
4 Innovation External Innovation to Accelerate Replenishment of Pipeline and Broaden Modalities Selected High-Level Overview Momentum Significantly Increased >40 Transactions signed since 2020 • Deals covering the entire spectrum from equity investments (with LEAPS), over licensing agreements to acq
Slide 52: Elinzanetant Addresses High Unmet Needs for Non-hormonal Treatment
4 Innovation Elinzanetant Addresses High Unmet Needs for Non-hormonal Treatment of Vasomotor Symptoms in Menopausal Women Elinzanetant Typical Vasomotor Symptoms • A first-in-class, non-hormonal, once-daily, oral During Menopause neurokinin-1,3 receptor antagonist • Differentiated, double mode of ac
Slide 53: Significant Progress in Anti-coagulation Therapy but Medical Need Still Exists
4 Innovation Significant Progress Has Been Achieved in Anti-coagulation Therapy but Medical Need Still Exists NOACs Vitamin K Direct Direct FXa Heparin Antagonists LMWH Thrombin Inhibitors (VKA) Inhibitors • Heparin and VKAs were the only anticoagulants available for most of the 20th century • Guide
Slide 54: Bayer Has a World Leading Factor XI(a) Portfolio
4 Innovation Bayer Has a World Leading Factor XI(a) Portfolio – Next Class of Anticoagulation Drug Candidates with Disruptive Potential Asset Mode of Action Comprehensive Phase IIb Program Antisense technology prevents FXI expression • RE-THINc ESRD Data to be presented in 2022 FXI-Antisense (IONIS-
Slide 55: Hereditary Factor XI Deficiency Associated with Lower Risk of Thrombotic Events
4 Innovation Hereditary Factor XI Deficiency is Associated with Lower Risk for Cardiovascular and Venous Thromboembolic Events Rate of Venous Thromboembolism Rate of Cardiovascular Events depending on FXI Level depending on FXI Level Factor XI >50% Rate of venous thromboembolism Rate of cardiovascul
Slide 56: Advancing Leading CGT Platform with Strong Clinical Pipeline
4 Innovation Advancing Leading CGT Platform with Strong Clinical Pipeline Example: Two-pronged approach to deliver transformative therapies to treat Parkinson’s Diverse tech platforms and capabilities AAV platform (AskBio and Successful administration Bayer established) of first dose of DA011 to a B
Slide 57: Bayer Pharmaceuticals: Overview Development Portfolio
4 Innovation Bayer Pharmaceuticals: Overview Development Portfolio (as of March 1, 2022) Phase I (23) Phase II (14) Phase III (10) Elimusertib (ATR Inhibitor) Regorafenib* (combi Nivolumab) Darolutamide (AR Inhibitor) /// Solid tumors (recurrent or metastatic) /// Prostate Cancer (mHSPC) (ARASENS) R
Slide 58: Winning in Consumer Health
Science for a Better Life Winning in Consumer Health /////////// Investment Case April 2022 / Bayer AG 58 /// Bayer AG /// Investment Case /// April 2022
Slide 59: Winning in Consumer Health
Winning in Consumer Health 1 Market & Position 2 Strategy 3 Sustainability 59 /// Bayer AG /// Investment Case /// April 2022
Slide 60: Consumer Health: A Leading Global OTC Player
1 Market & Position Consumer Health: A Leading Global OTC Player Sales development EBITDA margin development Sales by region: €5.3bn % yoy cpa In %, before special items In %, in 2021 FINANCIALS 22,5% 6.5% 22,0% North 34 EMEA 5.2% 20,9% America 39 2.6% 11 16 Asia / Pacific Latin 2019 2020 2021 2019
Slide 61: A Multifaceted Plan to Drive Further Growth
2 Strategy A Multifaceted Plan to Drive Further Growth AMBITION Grow ahead of the market and increase margins WHERE Winning & Balanced Portfolio TO PLAY Growth Modern Optimized HOW focused Innovation Cost & Cash Marketing & Sales TO WIN (esp. in powerbrands) (e.g. precision marketing) (with focus on
Slide 62: Driving Disproportionate Growth in Attractive Segments and Markets
2 Strategy: Growth-Focused Capital Allocation Driving Disproportionate Growth in Attractive Segments and Markets Strong positions in 7 out of Top 10 OTC markets Top 5 position Accelerate growth in fast-growing and profitable markets USA CHINA India South-East Asia 62 /// Bayer AG /// Investment Case
Slide 63: Accelerating Growth from Innovation
2 Strategy: Growth-Focused Innovation Accelerating Growth from Innovation Iconic Global and Local Brands Built over Decades 1898 1930 1934 1940 1943 1950 1983 1992 Note: xx = Year of brand launch 63 /// Bayer AG /// Investment Case /// April 2022
Slide 64: Modernizing Our Brand Building and Sales Capabilities
2 Strategy: Modernized Marketing & Sales Modernizing Our Brand Building and Sales Capabilities Brands with Purpose From Mass to Precision Marketing % Precision 25% 58% 80% marketing1 2018 2021 2024 - Ambition Accelerating E-commerce 3% 10% 15%+ % Net Sales2 2018 2021 2024 - Ambition 1 Percentage of
Slide 65: Taking Bold Steps on Sustainability
3 Sustainability Taking Bold Steps on Sustainability Expand access to everyday health for 2030 Goal 100 million underserved consumers Societal Environmental Health Literacy Accessible Products Carbon Neutral Production Sustainable Products Partnerships & brand purpose Affordable formats, innovations
Slide 66: Sustainability @Bayer
Science for a Better Life Sustainability @Bayer /////////// Investment Case April 2022 / Bayer AG 66 /// Bayer AG /// Investment Case /// April 2022
Slide 67: Sustainability is Integral to Our Values, Strategy and Operations
ESG Overview Group Sustainability is Integral to Our Values, Strategy and Operations We intend to create bold impact and generate sustainable business opportunities Pharmaceuticals Consumer Health Crop Science Megatrends Aging Population Growing Population Pressure on Ecosystems Preserve and Secure
Slide 68: Sustainable Innovation as Foundation for Business Opportunities
ESG Sustainable Innovation as Foundation for Business Opportunities Co-Shaping the We are among the companies that help to shape the ongoing bio-revolution. Our extensive knowledge of human and plant science, supported by our expertise in regulatory Bio-Revolution processes and a global footprint ul
Slide 69: Ambitious Measurable Targets for Sustainable Development
ESG Overview Group Ambitious Measurable Targets for Sustainable Development Our 2030 Targets are in line with UN SDGs and the Science Based Targets Initiative Decrease ECOLOGICAL footprint Help more PEOPLE thrive Climate neutrality at own sites + Support 100m smallholder farmers in LMIC3 reduced emi
Slide 70: We Take Broad Climate Action Along the Value Chain
ESG We Take Broad Climate Action Along the Value Chain 42% less CO2 in our own operations1 by 2029 12.3% less CO2 in the value chain2 by 2029 30% less greenhouse gas emissions3 by 2030 Reduce Carbon Emissions Net Zero by 2050 Reduction Offset remaining emissions with increasing share of removals Gen
Slide 71: We Are on Track in our Decarbonization Journey
We Are on Track in our Decarbonization Journey • Reduced emissions by 11.5% or around 410,000 tons compared to 2020 3.76 3.58 42% less CO2 in our 3.17 2.152 • Reduction mostly due to increase of renewable energy own operations share to approx. 25% of total purchased energy by 2029 & 100% -4.8% -11.5
Slide 72: Support 100m Smallholder Farmers
Support 100m Smallholder Farmers Accessing smallholders improves lives and creates business opportunities Progress Commercial Forecast & Initiatives Challenges 100 45 49 42 • Commercial operations: 2019 2020 2021 2030 Regional commercial strategies focused on smallholders’ needs (baseline) How to ge
Slide 73: Access for 100m Women to Family Planning
Access for 100m Women to Family Planning Catalyst for important societal and economic impact Progress • >200 million women in developing regions who want to avoid pregnancy are not using safe and effective family planning methods, central to women’s empowerment Bayer Products & Capacity Building1 Ch
Slide 74: Access to Self-Care for 100m People in Underserved Communities
Access to Self-Care for 100m People in Underserved Communities Everyday health as the first and last line of care Progress • Ageing population, a rise in lifestyle related diseases and a constantly increasing level of Challenges healthcare costs Access Driven Growth & Strategic Partnerships • Expand
Slide 75: Strong Governance Measures Accompany our Strategy
ESG Strong Governance Measures Accompany our Strategy Our CEO is Chief Sustainability Officer Established Governance Bodies • Supervisory Board ESG Committee advises & monitors management, systematically assesses contribution to SDGs • External Sustainability Council1 as institutionally anchored ind
Slide 76: Investment Thesis: Key Takeaways
Key Takeaways Group Overview Investment Thesis Key Takeaways 1 We are a global leader in Health & Nutrition that addresses societal megatrends 2 We are well-positioned to shape disruption in the bio-revolution 3 We expect to translate innovation into profitable mid-term growth 4 We expect to improve
Slide 77: A Global Leader in Health & Nutrition
Science for a Better Life A Global Leader in Health & Nutrition /////////// Investment Case April 2022 / Bayer AG 77 /// Bayer AG /// Investment Case /// April 2022